China’s CanSino defends Covid-19 vaccine candidate after experts cast doubt | Malay Mail

Wednesday, 09 Sep 2020 02:14 PM MYT

SHANGHAI, Sept 9 — China’s CanSino Biologics Inc said today that expert opinion on its high-profile coronavirus vaccine candidate should not be followed “blindly” without sufficient clinical trial data. “Vaccine development is a practice-based science, and we should not blindly follow experts,” Zhu Tao, chief scientific officer, said during an investor conference.

No evidence showed that existing antibodies against the common cold could have a major adverse impact on Ad5-nCoV’s ability to trigger antibodies against the novel coronavirus, Zhu said, citing results from 128 participants tested with a lower dose of the vaccine candidate in a mid-stage trial.Vaccine companies normally have to collect data in large-scale, late-stage trials to obtain regulatory approval for mass use.

Business Business Latest News, Business Business Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

AstraZeneca pauses Covid-19 vaccine trial after unexplained illness | Malay MailWASHINGTON, Sept 9 — Pharmaceutical company AstraZeneca said yesterday it had “voluntarily paused” a randomised clinical trial of its coronavirus vaccine in what it called a routine action after a volunteer developed an unexplained illness. The company, which is developing the drug alongside...
Source: malaymail - 🏆 1. / 86 Read more »